1. Home
  2. SLRX vs VTAK Comparison

SLRX vs VTAK Comparison

Compare SLRX & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Salarius Pharmaceuticals Inc.

SLRX

Salarius Pharmaceuticals Inc.

HOLD

Current Price

$0.78

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Logo Catheter Precision Inc.

VTAK

Catheter Precision Inc.

HOLD

Current Price

$2.53

Market Cap

4.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLRX
VTAK
Founded
N/A
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
4.1M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
SLRX
VTAK
Price
$0.78
$2.53
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
664.7K
54.2K
Earning Date
11-14-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$730,000.00
Revenue This Year
N/A
$822.86
Revenue Next Year
N/A
$168.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
82.96
52 Week Low
$0.71
$1.49
52 Week High
$108.00
$15.68

Technical Indicators

Market Signals
Indicator
SLRX
VTAK
Relative Strength Index (RSI) 26.09 54.17
Support Level $0.81 $2.26
Resistance Level $0.89 $3.06
Average True Range (ATR) 0.07 0.25
MACD 0.10 0.08
Stochastic Oscillator 0.00 62.32

Price Performance

Historical Comparison
SLRX
VTAK

About SLRX Salarius Pharmaceuticals Inc.

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

About VTAK Catheter Precision Inc.

Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.

Share on Social Networks: